Gh Research Plc's Comment on Sales, Marketing and Customers
The company operates in the treatment-resistant depression (TRD) market, competing with major pharmaceutical, specialty pharmaceutical, biotechnology companies, academic institutions, non-profit organizations, governmental agencies, and medical research organizations. Notable competitors include Janssen, which markets SPRAVATO® (esketamine), and companies developing tryptamine compounds such as AtaiBeckley, Axsome Therapeutics, COMPASS Pathways, Helus Pharma, and Definium Therapeutics. COMPASS Pathways' investigational therapy COMP360 is currently the most advanced in clinical development for TRD. The company competes in markets involving pharmacological and somatic therapies for TRD and major depressive disorder (MDD) patients who have not responded to two or more MDD pharmacotherapies. It seeks to protect its innovations through patents and trade secrets to maintain its competitive position.
GH Research Receives European Patent for Mebufotenin (5-MeO-DMT) and Salt Products in the Treatment of Major Depressive Disorder and Treatment-Resistant DepressionDUBLIN, Ireland, Jan. 18, 2024 - GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of psychiatric and neurological disorders, announced today that it has been granted a patent by the European Patent Office (EPO) for the use of mebufotenin (5-MeO-DMT) or a pharmaceutically acceptable salt of mebufotenin in treating patients suffering from major depressive disorder (MDD) and its treatment-resistant forms, including treatment-resistant depression (TRD).Major depressive disorder and trea...
Gh Research Plc’s Comment on Sales, Marketing and Customers
The company operates in the treatment-resistant depression (TRD) market, competing with major pharmaceutical, specialty pharmaceutical, biotechnology companies, academic institutions, non-profit organizations, governmental agencies, and medical research organizations. Notable competitors include Janssen, which markets SPRAVATO® (esketamine), and companies developing tryptamine compounds such as AtaiBeckley, Axsome Therapeutics, COMPASS Pathways, Helus Pharma, and Definium Therapeutics. COMPASS Pathways' investigational therapy COMP360 is currently the most advanced in clinical development for TRD. The company competes in markets involving pharmacological and somatic therapies for TRD and major depressive disorder (MDD) patients who have not responded to two or more MDD pharmacotherapies. It seeks to protect its innovations through patents and trade secrets to maintain its competitive position.
Sources:
Gh Research Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Gh Research Plc’s corporate clients.
For your research, we’ve provided 9 tables on Gh Research Plc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
